Blog

HY Immunity and Pregnancy: Research Review

HY Immunity and Pregnancy: Research Review

Embryos with a Y chromosome have proteins called HY antigens (male specific minor histocompatibility antigen) on their cells. Occasionally, when a mother gives birth to a boy / baby with a Y chromosome, the mother’s immune system can generate an immune response against these HY antigens and interfere with future pregnancies.

The mother’s human leukocyte antigens (HLAs) are responsible for initiating this immune response, and some HLA alleles increase the likelihood of this happening. IRMA’s HY Immunity assessment determines if the patient carries these higher-risk HY restricting alleles, which might put the patient at higher risk if they’ve previously given birth to a boy. (An allele is an alternate version of a gene at a specific location of the chromosome.)

Physiology

During a first pregnancy with a male fetus, the maternal immune system could be activated by allogenic fetal cells possessing male-specific minor histocompatibility inherited antigens (HYrHLA allele) that are encoded by genes localized on the Y chromosome. In some women, this can lead to an acute immune reaction leading to the production of HY antibodies by B cells. These antibodies can last for several years in the maternal serum1. This may lead to secondary recurrent miscarriage (with male or female embryos) and to giving birth to boys with a low birth weight2-3.

Published clinical data

Although present in 30% of women, anti HY antibodies have been linked to secondary recurrent miscarriage in subsequent pregnancy and other pregnancy complications such as stillbirth, placental abruption or fetal growth retardation, all these events being the results of an inflammatory environment.

A large cohort study including women with unexplained secondary RPL showed that these patients were more prone to miscarriage during their subsequent pregnancy when having a firstborn boy compared to a firstborn girl (46 % versus 24 % respectively)4.

In these patients with a first-born son, the presence of H-Y restricting HLA class II alleles (HLA-DRB1*15, HLA- DQB1*05:01/02 and HLA–DRB3*03:01) has been correlated with lower chance of live birth and a low male/female ratio among the subsequent births (increased loss rate of male embryos)5.

Patients with no copy of HY restricting alleles have a subsequent live birth rate of 73%, which dropped to 58% with 1 allele copy and 49% with two allele copies.

References

  1. Christiansen OB, Steffensen R, Nielsen HS. Anti-HY responses in pregnancy disorders. Am J Reprod Immunol. 2011 Jul;66 Suppl 1:93-100.
  2. Kolte AM, Steffensen R, Christiansen OB, Nielsen HS. Maternal HY-restricting HLA class II alleles are associated with poor long-term outcome in recurrent pregnancy loss after a boy. Am J Reprod Immunol. 2016 Nov;76(5):400-405.
  3. Nielsen HS, Steffensen R, Varming K, Van Halteren AG, Spierings E, Ryder LP, Goulmy E, Christiansen OB. Association of HY-restricting HLA class II alleles with pregnancy outcome in patients with recurrent miscarriage subsequent to a firstborn boy. Hum Mol Genet. 2009 May 1;18(9):1684-91.
  4. Christiansen OB, Steffensen R, Nielsen HS. The impact of anti-HY responses on outcome in current and subsequent pregnancies of patients with recurrent pregnancy losses. J Reprod Immunol. 2010 May;85(1): 9-14.
  5. Nielsen HS, Steffensen R, Varming K, Van Halteren AG, Spierings E, Ryder LP, Goulmy E, Christiansen OB. Association of HY-restricting HLA class II alleles with pregnancy outcome in patients with recurrent miscarriage subsequent to a firstborn boy. Hum Mol Genet. 2009 May 1; 18(9): 1684-91.
Back to blog
We love questions

Talk to an expert

Pregmune’s fertility services experts are available to help you get started and to answer any questions you may have along the way.

Medical Disclaimer

Patients and physicians should always consult with a licensed medical professional before making any clinical decisions, including starting or discontinuing any treatment. Any information provided by Pregmune, including but not limited to the IRMA Report, AIMY Report, test results, risk estimates, supporting documentation, email communications or other related content (collectively, "Pregmune Content"), is intended for informational purposes only. This content is not medical advice and should not be used as a substitute for professional medical evaluation, diagnosis, or treatment. Pregmune Content is not a recommendation for any specific treatment plan, therapy, medication, or course of action. It is designed to support, not replace, the relationship between patients and their qualified healthcare providers. Pregmune does not provide medical care, and its reports and communications should never delay or override clinical judgment.